Research programme: neurodegenerative diseases therapeutics - Cyclica
Latest Information Update: 29 Mar 2022
At a glance
- Originator Cyclica
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 25 Mar 2022 Research programme: neurodegenerative diseases therapeutics - Cyclica/Arctoris is available for licensing as of 25 Mar 2022. https://www.cyclicarx.com/partners
- 23 Mar 2022 Cyclica and Arctoris agree to co-develop neurodegenerative diseases therapeutics for Alzheimer's disease and other Neurodegenerative disorders
- 23 Mar 2022 Early research in Alzheimer's disease in Canada (unspecified route)